Bisphosphonate related osteonecrosis of the jaws

Journal of Rheumatology

Volumn 36, Issue 2, 2009, Pages 451-452

  Campisi, Giuseppina ^a   Fedele, Stefano ^b   Colella, Giuseppe ^c   Lo Casto, Antonio ^a   Fusco, Vittorio ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d C Arrigo Children's Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

BONE INFECTION; CANCER RADIOTHERAPY; DENTAL CARE; DENTAL SURGERY; DRUG SAFETY; EVIDENCE BASED PRACTICE; HUMAN; JAW OSTEONECROSIS; LETTER; LOW DRUG DOSE; MOUTH DISEASE; MOUTH HYGIENE; NEOPLASM; OSTEOPOROSIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; TOOTH DISEASE; BONE NECROSIS; CANADA; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; EPIDEMIOLOGY; INCIDENCE; JAW DISEASE; MONITORING; NOTE; PERIODONTAL DISEASE; PREVENTIVE DENTISTRY; STANDARD;

BONE DENSITY CONSERVATION AGENTS; CANADA; CAUSALITY; DIAGNOSIS, DIFFERENTIAL; DIPHOSPHONATES; HUMANS; INCIDENCE; JAW DISEASES; MONITORING, PHYSIOLOGIC; OSTEONECROSIS; OSTEOPOROSIS; PERIODONTAL DISEASES; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE DENTISTRY; RISK REDUCTION BEHAVIOR;

EID: 64849087584     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080843     Document Type: Letter

References (22)

1. Khan AA, Sándor GK, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008;35:1391-1397
2. Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 2008;14:277-285
3. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006;137:1144-1150
4. Merck reports first-quarter 2008 financial results. Internet. Available at: http://www.merck.com/newsroom/press-releases/financial/ 2008-0421.html. Accessed Oct 27 2008.
5. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-376
6. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423
7. Khan AA. Osteonecrosis of the jaw: new developments in an old disease [editorial]. J Rheumatol 2008;35:547-549
8. National Institute of Dental Research. Oral health of United States adults, the national survey of oral health in U.S. employed adults and seniors: 1985-1986. Bethesda, MD: National Institute of Dental Research; 1987 (NIH publication no. 87-2868).
9. Douglass CW. Risk assessment and management of periodontal disease. J Am Dent Assoc 2006;137:27S-32S.
10. McLeod NMH, Davies BJB, Brennan PA. Bisphosphonate osteonecrosis of the jaws; an increasing problem for the dental practitioner. Br Dent J 2007;203:641-644
11. McMahon RE, Bouquot JE, Glueck CJ, Spolnik KJ, Adams WR. Osteonecrosis: a multifactorial etiology. J Oral Maxillofac Surg 2004;62:904-905
12. Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:249-258
13. Bedogni A, Blandamura S, Lokmic Z, et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:358-364
14. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:1658-1668
15. Khosla S, Burr D, Cauley J, et al. American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491
16. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575
17. La Rete Oncologica del Piemonte e della Valle d'Aosta. [Internet. Accessed Oct 27 2008.] Available from: www.reteoncologica.it.
18. Agenzia Italiana Del Farmaco. Determinazione 9 novembre 2006. Modifica degli stampati di specialita' medicinali contenenti bifosfonati (escluso acido pamidronico e acido zoledronico). [Internet. Accessed Oct 27 2008.] Available from: http://www. guritel.it/free-sum/ARTI/2006/11/16/sommario.html.
19. Department of Health and Ageing. Australian Adverse Drug Reactions Bulletin. Volume 25, Number 4, August 2006. Osteonecrosis of the jaw with bisphosphonates. [Internet. Accessed Oct 27 2008.] Available from: http://www.tga.gov.au/adr/aadrb/aadr0608.htm#a1.
20. Medicines and Healthcare Products Regulatory Agency. Drug Safety Update, Issue 3, October 2007. [Internet. Accessed Oct 27 2008.] Available from: http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafety Update/CON2032518.
21. European Medicines Agency. List of the names, pharmaceutical form, strength of the medicinal product, route of administration, applicant, marketing authorisation holder in the member states. [Internet. Accessed Oct 27 2008.] Available from: http://www.emea.europa.eu/pdfs/human/referral/ alendronatehexal766/ AlendronateHexal-AnnexI-III-en.pdf.
22. National Institutes of Health. Drugs, supplements, and herbal information. [Internet. Accessed Oct 27 2008.] Available from: http://www.nlm.nih.gov/medlineplus/druginformation.html.